Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2021 Dec 24

PMID 34943916

Citations 5

Authors

Giulia Scotto

Fulvio Borella

Margherita Turinetto

Valentina Tuninetti

Anna A Valsecchi

Gaia Giannone

Stefano Cosma

Chiara Benedetto

Giorgio Valabrega

Affiliations

Soon will be listed here.

Abstract

Epithelial ovarian cancer (EOC) is the leading cause of death among women affected by gynaecological malignancies. Most patients show advanced disease at diagnosis (FIGO stage III-IV) and, despite the introduction of new therapeutic options, most women experience relapses. In most cases, recurrence is abdominal-pelvic; however, EOC can occasionally metastasize to distant organs, including the central nervous system. The incidence of brain metastases (BMs) from EOC is low, but it has grown over time; currently, there are no follow-up strategies available. In the last decade, a few biomarkers able to predict the risk of developing BMs from OC or as potential therapeutic targets have been investigated by several authors; to date, none have entered clinical practice. The purpose of this review is to offer a summary on the role of the most relevant predictors of central nervous system (CNS) involvement (hormone receptors; BRCA; MRD1; PD-1/PD-L1) and to highlight possible therapeutic strategies for the management of metastatic brain disease in EOC.

Citing Articles

PARP Inhibitors in Brain Metastases from Epithelial Ovarian Cancer through a Multimodal Patient Journey: Case Reports and Literature Review.

Frezzini S, Tasca G, Borgato L, Sartor L, Ferrero A, Artioli G Int J Mol Sci. 2024; 25(14).

PMID: 39063128 PMC: 11276770. DOI: 10.3390/ijms25147887.

The Ovary-Brain Connection.

Yousif A, Ebeid A, Kacsoh B, Bazzaro M, Chefetz I Cells. 2024; 13(1).

PMID: 38201298 PMC: 10778337. DOI: 10.3390/cells13010094.

Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options.

Borella F, Fucina S, Mangherini L, Cosma S, Carosso A, Cusato J Biomedicines. 2023; 11(8).

PMID: 37626654 PMC: 10452581. DOI: 10.3390/biomedicines11082157.

Sustained delivery of PARP inhibitor Talazoparib for the treatment of -deficient ovarian cancer.

Yang S, Green A, Brown N, Robinson A, Senat M, Testino B Front Oncol. 2023; 13:1175617.

PMID: 37228496 PMC: 10203577. DOI: 10.3389/fonc.2023.1175617.

From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia.

Borella F, Cosma S, Ferraioli D, Preti M, Gallio N, Valabrega G Front Oncol. 2022; 12:859071.

PMID: 35493999 PMC: 9045690. DOI: 10.3389/fonc.2022.859071.

References

Bangham M, Goldstein R, Walton H, Ledermann J . Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease. Gynecol Oncol Rep. 2016; 18:22-24. PMC: 5081421. DOI: 10.1016/j.gore.2016.10.004. View

Sakamoto I, Hirotsu Y, Nakagomi H, Ikegami A, Teramoto K, Omata M . Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: A case report. J Obstet Gynaecol Res. 2018; 45(3):743-747. DOI: 10.1111/jog.13851. View

Sekine M, Yoshihara K, Komata D, Haino K, Nishino K, Tanaka K . Increased incidence of brain metastases in BRCA1-related ovarian cancers. J Obstet Gynaecol Res. 2012; 39(1):292-6. DOI: 10.1111/j.1447-0756.2012.01961.x. View

Szarszewska M, Markowska A, Jach R, Marszalek A, Filas V, Bednarek W . Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study. Adv Med Sci. 2019; 64(2):235-240. DOI: 10.1016/j.advms.2018.12.007. View

Langdon S, Herrington C, Hollis R, Gourley C . Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer. Cancers (Basel). 2020; 12(6). PMC: 7352420. DOI: 10.3390/cancers12061647. View

Mirza M, Pignata S, Ledermann J . Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. Ann Oncol. 2018; 29(6):1366-1376. DOI: 10.1093/annonc/mdy174. View

Lazennec G . Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett. 2006; 231(2):151-7. PMC: 1942069. DOI: 10.1016/j.canlet.2005.01.021. View

Borella F, Ghisoni E, Giannone G, Cosma S, Benedetto C, Valabrega G . Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. Diagnostics (Basel). 2020; 10(3). PMC: 7151145. DOI: 10.3390/diagnostics10030146. View

Thomakos N, Diakosavvas M, Machairiotis N, Fasoulakis Z, Zarogoulidis P, Rodolakis A . Rare Distant Metastatic Disease of Ovarian and Peritoneal Carcinomatosis: A Review of the Literature. Cancers (Basel). 2019; 11(8). PMC: 6721345. DOI: 10.3390/cancers11081044. View

10.

Voutsadakis I . Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations. Clin Med Insights Oncol. 2016; 10:17-25. PMC: 4814131. DOI: 10.4137/CMO.S32813. View

11.

Rutherford T, Brown W, Sapi E, Aschkenazi S, Munoz A, Mor G . Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet Gynecol. 2000; 96(3):417-21. DOI: 10.1016/s0029-7844(00)00917-0. View

12.

Gray S, Khor X, Yiannakis D . Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases. BMJ Case Rep. 2019; 12(8). PMC: 6721186. DOI: 10.1136/bcr-2019-230738. View

13.

Heinzelmann-Schwarz V, Knipprath Meszaros A, Stadlmann S, Jacob F, Schoetzau A, Russell K . Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients. Gynecol Oncol. 2017; 148(1):79-85. DOI: 10.1016/j.ygyno.2017.10.036. View

14.

Ratner E, Bala M, Louie-Gao M, Aydin E, Hazard S, Brastianos P . Increased risk of brain metastases in ovarian cancer patients with BRCA mutations. Gynecol Oncol. 2019; 153(3):568-573. DOI: 10.1016/j.ygyno.2019.03.004. View

15.

Gershenson D, Sun C, Iyer R, Malpica A, Kavanagh J, Bodurka D . Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2012; 125(3):661-6. PMC: 4405157. DOI: 10.1016/j.ygyno.2012.02.037. View

16.

Penson R, Oliva E, Skates S, Glyptis T, Fuller Jr A, Goodman A . Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol. 2004; 93(1):98-106. DOI: 10.1016/j.ygyno.2003.11.053. View

17.

Aalipour S, Zoghi S, Khalili N, Hirbod-Mobarakeh A, Emens L, Rezaei N . Specific immunotherapy in ovarian cancer: a systematic review. Immunotherapy. 2016; 8(10):1193-204. DOI: 10.2217/imt-2016-0034. View

18.

Vaidyanathan A, Sawers L, Gannon A, Chakravarty P, Scott A, Bray S . ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer. 2016; 115(4):431-41. PMC: 4985349. DOI: 10.1038/bjc.2016.203. View

19.

Coleman R, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A . Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390(10106):1949-1961. PMC: 5901715. DOI: 10.1016/S0140-6736(17)32440-6. View

20.

Cormio G, Loizzi V, Falagario M, Calace A, Colamaria A, De Tommasi A . Central nervous system metastases from epithelial ovarian cancer: prognostic factors and outcomes. Int J Gynecol Cancer. 2011; 21(5):816-21. DOI: 10.1097/IGC.0b013e318216cad0. View